Age-related survival and clinical features in systemic sclerosis patients older or younger than 65 at diagnosis

Rheumatology

Volumn 49, Issue 6, 2010, Pages 1112-1117

  Pérez Bocanegra, Carmen ^a   Solans Laqué, Roser ^a   Simeén Aznar, Carmen P ^a   Campillo, Mercedes ^b   Fonollosa Pla, Vicente ^a   Vilardell Tarrés, Miquel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Elderly; Mortality; Survival; Systemic sclerosis; Visceral involvement

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CAPILLAROSCOPY; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DIGESTIVE SYSTEM DISEASE; ESOPHAGUS DISEASE; FEMALE; HEART DISEASE; HUMAN; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SKIN DISEASE; SURVIVAL; SYSTEMIC SCLEROSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HEART DISEASES; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 77953514787     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq046     Document Type: Article

References (38)

1. Solans R, Motta C, Solà R et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis. Arthritis Rheum 2000; 43:894-900.
2. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007;9(Suppl. 2):S4.
3. Fonollosa V, Simeón CP. Esclerodermia. Med Clin 2004; 122:418-9.
4. Silman AJ. Epidemiology of scleroderma. Ann Rheum Dis 1991;50:846-53.
5. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. Le Roy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
7. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
8. Maricq HR, Spencer-Geen G, LeRoy EC. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's síndrome and dermatomyositis. Am J Med 1976;61:862-70.
9. Black CM. Scleroderma: clinical aspects. J Intern Med 1993;234:115-8.
10. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma. Arthritis Rheum 2000;43:444-51.
11. Altman R, Medsger TA Jr, Bloch D, Michel B. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
12. Simeon CP, Armadans L, Fonollosa V et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003;42:71-5.
13. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122-6.
14. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56.
15. Pu SJ, Luo SF, Wu YJ et al. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus 2000;9:96-100.
16. Pease CT, Bhakta BB, Devlin J et al. Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology 1999;38:228-34.
17. Marie I, Hatron PY, Levesque H et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine 1999;78:139-47.
18. Haga H, Johnsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren's syndrome. Scand J Rheumatol 1999;28:227-32.
19. Derk CT, Arlet CM, Jiménez SA. Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study. Clin Rheumatol 2006;25: 831-4.
20. Schachna L, Wigley FM, Chang B et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003;124:2098-104.
21. Walker UA, Tyndall A, CzirjákLet al. EUSTAR Co-authors. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma trials and research group database. Ann Rheum Dis 2007; 66:754-63.
22. Berger M, Haimonitz A, Tosh AV, Berdoff R, Goldberg E. Quantitative assessment of pulmonary hypertensiónin patients with tricuspid regurgitation using wave Doppler ultrasounds. J Am Coll Cardiol 1985;6:359.
23. Sánchez-Román J, Opitz CF, Kowal-Bielecka O, García-Hernández FJ, Castillo-Palma MJ, Pittrow D. for the EPOSS-OMERACT Group. Screening for PHA in patients with systemic sclerosis focus on Dopplerechocardiography. Rheumatology 2008;47:v33-5.
24. Castell J, Fraile M, Candell J et al. Myocardial perfusion imaging in scleroderma and Raynaud's phenomenon. Eur J Nucl Med 1992;19:660.
25. Traub YM, Shapiro AP, Rodnan GP et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Medicine 1985;62:335-52.
26. Taeger D, Sun Y, Keil U, Straif K. A stand-alone Windows application for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies. Epidemiology 2000;11:607-8.
27. Anonymous. Systemic sclerosis in old age. Br Med J 1979; 1:1313-4.
28. Medsger TA Jr, Masi AT. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 1971;74:714-21.
29. Laing TJ, Gillespie BW, Toth MB et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
30. Marie I, Dominique S, Levesque H et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001;45:346-54.
31. Hunter C, Champion MD. The heart in scleroderma. Rheum Dis Clin N Am 2008;34:181-90.
32. Meune C, Avouac J, Wahbi K et al. Cardiac involvement is systemic sclerosis assessed by tissue-Doppler echocardiography during routine care. A controlled study of 100 consecutive patients. Arthritis Rheum 2008;58: 1803-9.
33. Gilboe IM, Kvien TK, Uhlig T, Husby G. Sicca symptoms and secondary Sjögren's syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables. Ann Rheum Dis 2001; 60:1103-9.
34. Walston J, Hadley EC, Ferrucci L et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on aging research conference on frailty in older adults. J Am Geriatr Soc 2006;54:991-1001.
35. Ferri C, Valentini G, Cozzi F. for the Systemic Sclerosis Study Group of the Italian Society of Rheumatology. Systemic sclerosis. Demographic, clinical and serologic features in 1012 Italian patients. Medicine 2002;81: 139-53.
36. Scussel-Lonzetti L, Joyal F, Raynaud JP et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81:154-67.
37. Abu-Shakra M, Gulemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993;36:460-4.
38. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007;66:551-3.